Mar 02, 2023 4:01pm EST Calyxt Reports Fourth Quarter 2022 Financial Results and Provides Corporate Update
Feb 15, 2023 7:30am EST Calyxt, Inc. Announces its Filing of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC
Jan 17, 2023 6:30am EST Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company
Nov 18, 2022 11:00am EST Calyxt Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil
Nov 17, 2022 4:01pm EST Calyxt Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
Nov 03, 2022 4:01pm EDT Calyxt Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 01, 2022 7:00am EDT Calyxt Joins Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense Initiative, to Advance Sustainable Plant-Based Biomanufacturing
Oct 27, 2022 7:00am EDT Calyxt to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time
Oct 25, 2022 7:00am EDT Calyxt Successfully Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants
Oct 06, 2022 7:00am EDT Calyxt Announces Agreement with Evologic Technologies to Scale Production of its Plant-based Ingredients
